ImClone shares up after research results

In the US, shares of ImClone Systems were gaining ground in pre-market dealings this morning after the biotech firm said its early-stage cancer therapy research is yielding encouraging results.

ImClone said its anti-cancer compounds showed promise in pre-clinical research, which is done on animals.